{"id":862616,"date":"2025-06-23T09:34:36","date_gmt":"2025-06-23T13:34:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/"},"modified":"2025-06-23T09:34:36","modified_gmt":"2025-06-23T13:34:36","slug":"cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/","title":{"rendered":"CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236"},"content":{"rendered":"
\n

SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (\u201cCERo\u201d or the \u201cCompany\u201d), an immunotherapy company developing the next generation of engineered T cell therapeutics targeting TIM4L with phagocytic mechanisms, today announces the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of lead compound CER-1236. Following an evaluation from the trial\u2019s Dose Escalation Safety Committee, preliminary results show that the patient demonstrated no dose limiting toxicity. The Company anticipates dosing the second patient in the cohort shortly.<\/p>\n

CERo CMO Robert Sikorski MD., PhD. noted, \u201cThe first patient experienced no dose-limiting toxicities during the planned 28-day observation period following the successful manufacturing of CER-1236 from an AML patient. A second AML patient has been identified and has provided informed consent for participation in the trial.\u201d<\/p>\n

CERo CEO Chris Ehrlich added, \u201cGiven that CER-1236 is a first-in-class biologic targeting a previously unexplored pathway, each milestone reached is significant. We remain focused on progressing methodically through each phase of this trial and are preparing to initiate our second trial of CER-1236 in solid tumors later this year. We continue to believe CER-1236 holds significant potential as a novel approach in cancer therapy and look forward to providing future updates.\u201d<\/p>\n

CER-1236 is currently in Phase 1 clinical trials for AML. The first-in-human, multi-center, open label, Phase 1\/1b study, titled, \u201cPhase 1\/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell\u00a0CER-1236\u00a0in Patients With Acute Myeloid Leukemia (CertainT-1),\u201d is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia that is either relapsed\/refractory, or in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated MDS\/AML or AML. The two-part study has begun with dose escalation to determine highest tolerated dose and recommended dose for Phase 2, followed by an expansion phase to evaluate safety and efficacy. Primary outcome measures include incidence of adverse events (AEs) and serious adverse events (SAEs), incidence of dose limited toxicities and estimation of overall response rate (ORR), complete response (CR), composite complete response (cCR), and measurable residual disease (MRD). Secondary outcome measures include pharmacokinetics (PK).<\/p>\n

\n About CERo Therapeutics Holdings, Inc.<\/strong>\n <\/p>\n

CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body\u2019s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (\u201cCER-T\u201d). CERo believes that this differentiated activity of CER-T cells could afford greater therapeutic application than currently approved chimeric antigen receptor (\u201cCAR-T\u201d) cell therapy. In April 2025, CERo initiated clinical trials for its lead product candidate, CER-1236, targeting TIM4L in both hematologic malignancies and solid tumors<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo and CERo\u2019s ability to regain compliance with Nasdaq continued listing standards. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201cwould\u201d and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo\u2019s management.<\/p>\n

Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo\u2019s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 15, 2025 and its subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo\u2019s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.<\/p>\n

\n Contact:<\/strong>
\n
Chris Ehrlich
Chief Executive Officer
cehrlich@cero.bio<\/a><\/p>\n

\n Investors:<\/strong>
\n
CORE IR
investors@cero.bio<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (\u201cCERo\u201d or the \u201cCompany\u201d), an immunotherapy company developing the next generation of engineered T cell therapeutics targeting TIM4L with phagocytic mechanisms, today announces the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of lead compound CER-1236. Following an evaluation from the trial\u2019s Dose Escalation Safety Committee, preliminary results show that the patient demonstrated no dose limiting toxicity. The Company anticipates dosing the second patient in the cohort shortly. CERo CMO Robert Sikorski MD., PhD. noted, \u201cThe first patient experienced no dose-limiting toxicities during the planned 28-day observation period following the successful manufacturing of CER-1236 from an AML … <\/p>\n

Continue reading “CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-862616","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (\u201cCERo\u201d or the \u201cCompany\u201d), an immunotherapy company developing the next generation of engineered T cell therapeutics targeting TIM4L with phagocytic mechanisms, today announces the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of lead compound CER-1236. Following an evaluation from the trial\u2019s Dose Escalation Safety Committee, preliminary results show that the patient demonstrated no dose limiting toxicity. The Company anticipates dosing the second patient in the cohort shortly. CERo CMO Robert Sikorski MD., PhD. noted, \u201cThe first patient experienced no dose-limiting toxicities during the planned 28-day observation period following the successful manufacturing of CER-1236 from an AML … Continue reading "CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-23T13:34:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4MjQ2OCM3MDEyNTgwIzUwMDEyNDM5MA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236\",\"datePublished\":\"2025-06-23T13:34:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\\\/\"},\"wordCount\":922,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4MjQ2OCM3MDEyNTgwIzUwMDEyNDM5MA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\\\/\",\"name\":\"CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4MjQ2OCM3MDEyNTgwIzUwMDEyNDM5MA==\",\"datePublished\":\"2025-06-23T13:34:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4MjQ2OCM3MDEyNTgwIzUwMDEyNDM5MA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4MjQ2OCM3MDEyNTgwIzUwMDEyNDM5MA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/","og_locale":"en_US","og_type":"article","og_title":"CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 - Market Newsdesk","og_description":"SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (\u201cCERo\u201d or the \u201cCompany\u201d), an immunotherapy company developing the next generation of engineered T cell therapeutics targeting TIM4L with phagocytic mechanisms, today announces the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of lead compound CER-1236. Following an evaluation from the trial\u2019s Dose Escalation Safety Committee, preliminary results show that the patient demonstrated no dose limiting toxicity. The Company anticipates dosing the second patient in the cohort shortly. CERo CMO Robert Sikorski MD., PhD. noted, \u201cThe first patient experienced no dose-limiting toxicities during the planned 28-day observation period following the successful manufacturing of CER-1236 from an AML … Continue reading \"CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-23T13:34:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4MjQ2OCM3MDEyNTgwIzUwMDEyNDM5MA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236","datePublished":"2025-06-23T13:34:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/"},"wordCount":922,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4MjQ2OCM3MDEyNTgwIzUwMDEyNDM5MA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/","name":"CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4MjQ2OCM3MDEyNTgwIzUwMDEyNDM5MA==","datePublished":"2025-06-23T13:34:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4MjQ2OCM3MDEyNTgwIzUwMDEyNDM5MA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4MjQ2OCM3MDEyNTgwIzUwMDEyNDM5MA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cero-therapeutics-holdings-inc-announces-first-patient-completes-dose-limiting-toxicity-observation-period-with-no-reported-dlts-in-phase-1-trial-of-cer-1236\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/862616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=862616"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/862616\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=862616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=862616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=862616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}